Top

Published in:

01-04-2008 | Preclinical Studies

Topical henna for capecitabine induced hand–foot syndrome

Authors: Idris Yucel, Gonullu Guzin

Published in: Investigational New Drugs | Issue 2/2008

Summary

Capecitabine is a chemotherapeutic drug for use in cancers. Hand–foot syndrome (HFS) is side effect of capecitabine which can lead the cessation of the therapy or dose reduction. Henna (Lawsonia inermis) is a traditionally used plant of Middle-East that is applied on hands and feet. Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna. In these patients, six patients were grade 3 HFS and four were grade 2 HFS. Complete response (CR) were seen in four of grade 3 HFS and all of grade 2; two grade 3 HFS improved to grade 1. So far, in the chemotherapy, there was no need of dose reduction and also no side effect of henna seen. Clinical improvement in these patients may relate to anti-inflammatory, antipyretic and analgesic effects of henna. Prospective studies are needed to show this therapeutic effect of henna.

Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem 8:1697–1706PubMedCrossRef

Marsé H, Van Cutsem E, Grothey A, Valverde S (2004) Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8:16–30CrossRef

Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar–plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13:1781–1783PubMed

Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand–foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169–2173PubMedCrossRef

Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar–plantar erythrodysesthesia. Cancer Chemother Pharmacol 44:303–306PubMedCrossRef

Komamura H, Higashiyama M, Hashimoto K, Takeda K, Kimura H, Tani Y (1995) Three cases of chemotherapy-induced acral erythema. J Dermatol 22:116–121PubMed

Mortimer JE, Lauman MK, Tan B (2003) Pyridoxine treatment and prevention of hand–foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 9:161–166CrossRef

Kandil HH, al-Ghanem MM, Sarwat MA, al-Thallab FS (1996) Henna (Lawsonia inermis Linn.) inducing haemolysis among G6PD-deficient newborns. A new clinical observation. Ann Trop Paediatr 16:287–291PubMed

Mikhaeil BR, Badria FA, Maatooq GT, Amer MM (2004) Antioxidant and immunomodulatory constituents of henna leaves. Z Naturforsch [C] 59:468–476

10.

Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMed

11.

Lassere Y, Hoff P (2004) Management of hand–foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8:31–40CrossRef

12.

Mrozek-Orlowski ME, Frye DK, Sanborn Hm (1999) Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nursing Forum 26:753–762

13.

Gerbrecht BM (2003) Current Canadian experience with capecitabine. Cancer Nursing 26:161–167PubMedCrossRef

14.

Fabian CJ, Molina R, Slavik M, Dahlberg S, Girl S, Stephens R (1990) Pyridoxine therapy for palmar–plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57–63PubMedCrossRef

15.

Ali BH, Bashir AK, Tanira MO (1995) Anti-inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Pharmacology 51:356–363PubMedCrossRef

Title: Topical henna for capecitabine induced hand–foot syndrome
Authors: Idris Yucel
Gonullu Guzin
Publication date: 01-04-2008
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2008
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-007-9082-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2008

A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat

A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer

Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis

A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells

Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium

Keynote webinar | Spotlight on antibody–drug conjugates in cancer